eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA & Protein Simultaneously in Millions of Single Ce...
December 09 2014 - 6:30AM
Business Wire
eBioscience, an Affymetrix (Nasdaq:AFFX) business, announces the
availability of PrimeFlow™ RNA Assay, the first and only flow
cytometry assay capable of simultaneous detection of RNA and
protein within millions of cells at single-cell resolution. Current
flow cytometry applications are limited to antibody-based
interrogation of cell surface and intracellular proteins. With the
novel PrimeFlow assay, researchers can now incorporate the
simultaneous analysis of RNA transcripts and proteins to elevate
their understanding of single-cell dynamics.
“Single-cell analysis is a rapidly growing field in biomedical
research that yields an unprecedented level of information,” said
Filippos Porichis, PhD, Director of the Ragon Institute of MGH, MIT
and Harvard’s International Programs and first author of a newly
published Nature Communications paper citing the use of RNA
transcript with flow cytometry. “PrimeFlow RNA Assay enables high
throughput detection of RNA and protein expression; therefore, it
can be used to characterize, mechanistically and phenotypically,
co-expression of RNAs with the functional proteins at the
single-cell level. This assay, with a user-friendly protocol that
has many similarities with standard antibody-staining procedures
and data acquisition of flow cytometry, is an invaluable tool for
any immunology lab performing translational research.”
“The major advantage of this technology is the ability to
detect, with high sensitivity, mRNAs for which flow cytometry
antibodies against the corresponding proteins perform poorly or are
not available,” adds Dr. Daniel Kaufmann, Research and Clinical
Associate Professor, Dept. of Medicine, University of Montreal.
“Furthermore, the capability to directly measure non-coding RNAs,
whose critical functional roles are increasingly recognized, in a
heterogeneous cell population has vast potential applications in
cell biology.”
“Single-cell gene expression assays, such as PrimeFlow RNA
Assay, showcase one of the many exciting opportunities we have for
integrating cell analysis and genomics, which open up new avenues
for innovation and growth,” said Frank Witney, CEO and President of
Affymetrix. “PrimeFlow RNA Assay represents the capabilities and
expertise of eBioscience and Affymetrix brought together to enable
the scientific community to advance the understanding and
application of biology for a better world.”
To further discuss potential applications of PrimeFlow RNA
Assay, please email us at MarketingDept@ebioscience.com.
PLEASE NOTE: eBioscience and PrimeFlow are trademarks of
eBioscience, Inc., and Affymetrix and the Affymetrix logo are
trademarks of Affymetrix, Inc. All other trademarks and product
names are the property of their respective owners.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein, and gene
level, facilitating the rapid translation of bench-top research
into clinical and routine use for human health and wellness. The
Company provides leadership and support, partnering with customers
in pharmaceutical, diagnostic, and biotechnology companies, as well
as leading academic, government, and non-profit research institutes
in their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
65,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, Ohio,
San Diego, Vienna, and Singapore. The Company has about 1,100
employees worldwide and maintains sales
and distribution operations across Europe, Asia, and
Latin America. For more information about Affymetrix, please
visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2013, and other SEC reports for subsequent
quarterly periods.
Affymetrix, Inc.Media Contact:Mindy Lee-Olsen,
408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024